drugset / Trial / NCT03561259
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma
Timeline
- Start
- 2019-10-21
- Primary completion
- 2023-12-01
- Completion
- 2025-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 131I-MIBG | Protein / enzyme biologic | 18 mg/kg | Intravenous |
| Subject | Vorinostat | Small molecule | 180 mg/m2 | Oral |